SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2020

---

INMODE LTD.

---

(Exact name of registrant as specified in its charter)

Tavor Building, Sha’ar Yokneam

P.O. Box 533

Yokneam 2069206 Israel

 

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes ☐     No ☒

On March 23, 2020, InMode Ltd. (the “Company”) issued a press release providing an update regarding its business projections in light of the ongoing global health situation caused by the COVID-19 disesase. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated March 23, 2020

InMode Provides COVID-19 Business Update

Yokneam, Israel, March 23, 2020 InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today provided an update regarding its business activities in light of the ongoing global health situation caused by the COVID-19. As of today, InMode’s Q1 2020 revenue from devices and consumables is in line with its target. Based on the company’s strong position for continued growth once  the COVID-19 has subsided,  and since InMode does not have visibility for the coming months, at this time InMode management has decided not to adjust its 2020 guidance. The company will continue to monitor the situation.

InMode is currently maintaining its business activities as usual, with minimal impact to sales and manufacturing activities. The company is continuing research and development into new platforms and indications, in addition to furthering the regulatory processes for devices and indications worldwide. InMode continues to strengthen its supply chain, in order to ensure continued stability with respect to manufacturing capacity and reliable inventory. In addition, InMode continues to strengthen its worldwide distribution network. These activities include the establishment of a fully owned subsidiary for sales and marketing in France.

“InMode is strongly positioned to weather the uncertainty of the current global economic situation,” commented Moshe Mizrahy, CEO of InMode. “We are supporting our customers during these extraordinary circumstances, and we will do everything in our power to maintain customer loyalty during and after this period. Based on management’s confidence in the company’s growth potential, we are currently evaluating several near-term actions, which may include, among other things, a stock repurchase program after the blackout period.

“Based on expert projections and our own experience in previous crisis situations, we currently anticipate a gradual stabilization of the global health and economic situation by the beginning of the third quarter,” concluded Mr. Mizrahy.

InMode is a leader in the minimally invasive market, recognized as an innovative company that delivers exceptional results to physicians and their patients. The company’s product offering is comprised of eight platforms, four of which are surgical solutions. As of today, InMode’s worldwide installed base exceeds 5,200 platforms.

About InMode 

InMode is a leading global provider of innovative medical technologies.  InMode develops, manufactures, and markets devices harnessing novel radio-frequency ("RF") technology.  InMode strives to enable new emerging surgical procedures as well as improve existing treatments.  InMode has leveraged its medically-accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. 

For more information about InMode, please visit www.inmodemd.com.